L'intérêt à découvert pour Tenet Healthcare donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Tenet Healthcare. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Tenet Healthcare (NYSE:THC) Stock, Rapport sur les intérêts à découvert

TENET HEALTHCARE CORP

Tenet Healthcare

Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.

Tenet Healthcare Corporation Common Stock

Tenet Healthcare Corp

THC BIOMED INTL LTD ORD by THC BioMed Intl Ltd.

THC Biomed International Ltd

TH International Limited - Ordinary shares

TH International Ltd

TOHO CO LTD ADR by TOHO CO LTD.

THUNDER BRDG CAP PARTNERS IV INC CL A

THUNDER BRDG CAP PARTNERS IV INC UNIT 1 CL A & 1/5 WT EXP

THUNDER BRDG CAP PARTNERS IV INC WT EXP

THC THERAPEUTICS INC by THC Therapeutics, Inc.

THC Therapeutics Inc

Spinnaker ETF Series Cannabis ETF

During the last three months, 10 analysts shared their evaluations of Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $175.6, a high estimate of $230.00, and a low estimate of $137.00. This current average reflects an increase of 3.83% from the previous average price target of $169.12. 
<img src="https://www.benzinga.com/files/images/story/2025/1747256471_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Tenet Healthcare. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$154.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$171.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$189.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$137.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Jason Cassorla</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$165.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Tenet Healthcare. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Tenet Healthcare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Tenet Healthcare's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/THC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Tenet Healthcare analyst ratings.</a>
<h2>Get to Know Tenet Healthcare Better</h2>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Tenet Healthcare: Delving into Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Tenet Healthcare's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -2.7%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Tenet Healthcare's net margin excels beyond industry benchmarks, reaching 7.77%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Tenet Healthcare's ROE stands out, surpassing industry averages. With an impressive ROE of 9.72%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Tenet Healthcare's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.4%, the company showcases efficient use of assets and strong financial health.
Debt Management: Tenet Healthcare's debt-to-equity ratio is below the industry average. With a ratio of 3.15, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Demystifying Tenet Healthcare: Insights From 10 Analyst Reviews

B of A Securities analyst Kevin Fischbeck maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and raises the price target from $165 to $180.

News

Price Target

B of A Securities Maintains Buy on Tenet Healthcare, Raises Price Target to $180

Truist Securities analyst David Macdonald maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and raises the price target from $175 to $190.

Truist Securities Maintains Buy on Tenet Healthcare, Raises Price Target to $190

Goldman Sachs analyst Jamie Perse maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Neutral and raises the price target from $134 to $154.

Goldman Sachs Maintains Neutral on Tenet Healthcare, Raises Price Target to $154

Morgan Stanley analyst Craig Hettenbach maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $165 to $175.

Morgan Stanley Maintains Overweight on Tenet Healthcare, Raises Price Target to $175

These large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) shares rose 27.39% after the company reported better-than-expected financial results and raised <a href="https://www.benzinga.com//node/45149547" target="_blank" rel="noreferrer noopener">its FY25 sales guidance</a>. Several analysts <a href="https://www.benzinga.com/quote/duol/analyst-ratings" target="_blank" rel="noreferrer noopener">boosted the price forecast</a>.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) shares increased 24.15%.</li>
<li>Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) stock escalated 21.24% after the company reported better-than-expected financial results and raised <a href="https://www.benzinga.com//node/45061907" target="_blank" rel="noreferrer noopener">its FY25 adjusted EPS guidance</a>. Many analysts <a href="https://www.benzinga.com/quote/thc/analyst-ratings" target="_blank" rel="noreferrer noopener">boosted the price forecast</a>.</li>
<li>Carrier Global Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) stock upped 19.10% after it reported better-than-expected first-quarter financial results<a href="https://www.benzinga.com//node/45135625" target="_blank" rel="noreferrer noopener"> and raised its FY25 guidance</a>.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock upped 18.90%. Akeso, Inc. announced the Chinese Health Authorities, the National Medical Products Administration (NMPA) approved ivonescimab for a second indication based on the results of the Phase 3 <a href="https://www.benzinga.com//node/45046531" target="_blank" rel="noreferrer noopener">trial, HARMONi-2 or AK112-303</a>.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) stock upped 18.31% last week after the company announced it launched its commercial self-driving <a href="https://www.benzinga.com//node/45128218" target="_blank" rel="noreferrer noopener">trucking service in Texas</a>.</li>
<li>Arista Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) shares were up 16.83% after Rosenblatt upgraded the stock from Sell to Neutral and raised its <a href="https://www.benzinga.com/quote/anet/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $55 to $85</a>.</li>
<li>Trane Technologies plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) stock grew 14.83% after the company reported better-than-expected financial results and raised its FY25 GAAP EPS and <a href="https://www.benzinga.com//node/45108290" target="_blank" rel="noreferrer noopener">sales guidance above estimates</a>. Many analysts <a href="https://www.benzinga.com/quote/tt/analyst-ratings" target="_blank" rel="noreferrer noopener">boosted the price forecast</a>.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) shares escalated 13.90% f<a href="https://www.benzinga.com//node/45149628" target="_blank" rel="noreferrer noopener">ollowing strong quarterly sales</a>. Many analysts <a href="https://www.benzinga.com/quote/dxcm/analyst-ratings" target="_blank" rel="noreferrer noopener">revised the price forecast</a>.</li>
<li>XPO Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) shares increased 13.81%  after the company reported better-than-expected <a href="https://www.benzinga.com//node/45099967" target="_blank" rel="noreferrer noopener">first-quarter EPS results</a>. Many analysts <a href="https://www.benzinga.com/quote/xpo/analyst-ratings" target="_blank" rel="noreferrer noopener">revised the price forecast</a>.</li>
</ol>
Photo by DANIEL CONSTANTE via Shutterstock

Equities

Large Cap

Movers

Trading Ideas

ANET

CARR

CRWV

DUOL

DXCM

EXAS

SMMT

Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?

Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $161 to $171.

Barclays Maintains Overweight on Tenet Healthcare, Raises Price Target to $171

RBC Capital analyst Ben Hendrix maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Outperform and raises the price target from $183 to $189.

RBC Capital Maintains Outperform on Tenet Healthcare, Raises Price Target to $189

UBS analyst A.J. Rice maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and raises the price target from $217 to $230.

UBS Maintains Buy on Tenet Healthcare, Raises Price Target to $230

WIIM

Tenet Healthcare shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY2025 adjusted EPS guidance.

Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) raises FY2025 GAAP EPS guidance from $10.95-$12.47 to $11.37-$12.92 vs $11.99 analyst estimate..

Guidance

Tenet Healthcare Raises FY2025 GAAP EPS Guidance from $10.95-$12.47 to $11.37-$12.92 vs $11.99 Est

Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) raises FY2025 Adj EPS guidance from $11.74-$12.84 to $11.99-$13.12 vs $12.16 analyst estimate. Affirms FY2025 sales outlook from $20.60 billion-$21.00 billion to $20.60 billion-$21.00 billion vs $20.88 billion estimate.

Tenet Healthcare Raises FY2025 Adj EPS Guidance from $11.74-$12.84 to $11.99-$13.12 vs $12.16 Est; Affirms FY2025 Sales Guidance of $20.60B-$21.00B vs $20.88B Est

Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) reported quarterly earnings of $4.36 per share which beat the analyst consensus estimate of $3.14 by 38.85 percent. This is a 35.4 percent increase over earnings of $3.22 per share from the same period last year. The company reported quarterly sales of $5.22 billion which beat the analyst consensus estimate of $5.16 billion by 1.28 percent. This is a 2.70 percent decrease over sales of $5.37 billion the same period last year.

Earnings

Earnings Beats

Tenet Healthcare Q1 Adj. EPS $4.36 Beats $3.14 Estimate, Sales $5.22B Beat $5.16B Estimate

ACGL

AEYE

AMSF

APAM

ARCB

ARCC

ASTE

ASTL

ATRC

BBIO

BBVA

BGFV

BKNG

BRSP

CECO

CHCT

CLVT

CSGP

CVLT

DHIL

ENSG

ENVA

ESRT

ETWO

EXLS

FELE

FFIC

FIBK

FICO

FOUR

FRSH

FRST

FSLR

FYBR

HLMN

HOUS

HRZN

HSBC

HURN

ILPT

INCY

INTZ

JAKK

JBGS

JBLU

KNSA

LFUS

LGIH

Laboratory Corporation Of America Holdings

LOGI

LXFR

Earnings Scheduled For April 29, 2025

Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-29. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Tenet Healthcare will report an earnings per share (EPS) of $3.17.
Tenet Healthcare bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.61, leading to a 5.85% increase in the share price the following trading session.
Here's a look at Tenet Healthcare's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.83</td>
<td>2.33</td>
<td>1.89</td>
<td>1.45</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>3.44</td>
<td>2.93</td>
<td>2.31</td>
<td>3.22</td>
</tr>
<tr>
<td>Price Change %</td>
<td>6.0%</td>
<td>-3.0%</td>
<td>3.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745852634_0.png" alt="eps graph" />
<h3>Performance of Tenet Healthcare Shares</h3>
Shares of Tenet Healthcare were trading at $122.1 as of April 25. Over the last 52-week period, shares are up 10.22%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Insights Shared by Analysts on Tenet Healthcare</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Tenet Healthcare.
With 5 analyst ratings, Tenet Healthcare has a consensus rating of Outperform. The average one-year price target is $161.0, indicating a potential 31.86% upside.
<h3>Peer Ratings Comparison</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Encompass Health, Universal Health Services and Ensign Group, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Encompass Health, with an average 1-year price target of $122.33, suggesting a potential 0.19% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Universal Health Services, with an average 1-year price target of $219.86, suggesting a potential 80.07% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Ensign Group, with an average 1-year price target of $160.33, suggesting a potential 31.31% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary outlines pivotal metrics for Encompass Health, Universal Health Services and Ensign Group, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenet Healthcare</td>
<td>Outperform</td>
<td>-5.71%</td>
<td>$4.14B</td>
<td>7.95%</td>
</tr>
<tr>
<td>Encompass Health</td>
<td>Outperform</td>
<td>3.59%</td>
<td>$585.90M</td>
<td>7.17%</td>
</tr>
<tr>
<td>Universal Health Services</td>
<td>Neutral</td>
<td>11.08%</td>
<td>$3.71B</td>
<td>5.01%</td>
</tr>
<tr>
<td>Ensign Group</td>
<td>Outperform</td>
<td>15.49%</td>
<td>$178.91M</td>
<td>4.45%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Tenet Healthcare ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, Tenet Healthcare is at the top among its peers.
<h3>About Tenet Healthcare</h3>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Financial Milestones: Tenet Healthcare's Journey</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Challenges: Tenet Healthcare's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -5.71%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.27%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Tenet Healthcare's ROE excels beyond industry benchmarks, reaching 7.95%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Tenet Healthcare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.09% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 3.16, Tenet Healthcare adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/THC/earnings">To track all earnings releases for Tenet Healthcare visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Peek at Tenet Healthcare's Future Earnings

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$105.00</td>
<td>$35.3K</td>
<td>866</td>
<td align="right">366</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$115.00</td>
<td>$60.0K</td>
<td>332</td>
<td align="right">193</td>
</tr>
<tr>
<td>VSTM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$6.00</td>
<td>$25.6K</td>
<td>5.2K</td>
<td align="right">152</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$445.00</td>
<td>$119.4K</td>
<td>1</td>
<td align="right">98</td>
</tr>
<tr>
<td>PTCT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$49.00</td>
<td>$55.5K</td>
<td>2</td>
<td align="right">67</td>
</tr>
<tr>
<td>SYK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$390.00</td>
<td>$27.3K</td>
<td>137</td>
<td align="right">46</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$135.00</td>
<td>$27.2K</td>
<td>1.7K</td>
<td align="right">26</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$700.00</td>
<td>$76.8K</td>
<td>53</td>
<td align="right">10</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$530.00</td>
<td>$41.0K</td>
<td>119</td>
<td align="right">9</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding CRL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on May 16, 2025. Parties traded 58 contract(s) at a $105.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $35.3K, with a price of $610.0 per contract. There were 866 open contracts at this strike prior to today, and today 366 contract(s) were bought and sold. 
• Regarding THC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), we observe a put option sweep with neutral sentiment. It expires in 24 day(s) on May 16, 2025. Parties traded 70 contract(s) at a $115.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $60.0K, with a price of $860.0 per contract. There were 332 open contracts at this strike prior to today, and today 193 contract(s) were bought and sold. 
• Regarding VSTM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), we observe a call option trade with neutral sentiment. It expires in 59 day(s) on June 20, 2025. Parties traded 151 contract(s) at a $6.00 strike. The total cost received by the writing party (or parties) was $25.6K, with a price of $170.0 per contract. There were 5217 open contracts at this strike prior to today, and today 152 contract(s) were bought and sold. 
• Regarding ISRG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), we observe a call option trade with bearish sentiment. It expires in 87 day(s) on July 18, 2025. Parties traded 20 contract(s) at a $445.00 strike. The total cost received by the writing party (or parties) was $119.4K, with a price of $5972.0 per contract. There were 1 open contracts at this strike prior to today, and today 98 contract(s) were bought and sold. 
• For PTCT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>), we notice a call option sweep that happens to be bearish, expiring in 241 day(s) on December 19, 2025. This event was a transfer of 50 contract(s) at a $49.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $55.5K, with a price of $1110.0 per contract. There were 2 open contracts at this strike prior to today, and today 67 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a call option sweep that happens to be bearish, expiring in 150 day(s) on September 19, 2025. This event was a transfer of 30 contract(s) at a $390.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $27.3K, with a price of $910.0 per contract. There were 137 open contracts at this strike prior to today, and today 46 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option sweep that happens to be bearish, expiring in 59 day(s) on June 20, 2025. This event was a transfer of 12 contract(s) at a $135.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $27.2K, with a price of $2270.0 per contract. There were 1737 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bullish, expiring in 115 day(s) on August 15, 2025. This event was a transfer of 5 contract(s) at a $700.00 strike. The total cost received by the writing party (or parties) was $76.8K, with a price of $15360.0 per contract. There were 53 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a put option trade with bearish sentiment. It expires in 150 day(s) on September 19, 2025. Parties traded 4 contract(s) at a $530.00 strike. The total cost received by the writing party (or parties) was $41.0K, with a price of $10250.0 per contract. There were 119 open contracts at this strike prior to today, and today 9 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ISRG

PTCT

VSTM

9 Health Care Stocks With Whale Alerts In Today's Session

Tenet Healthcare shares are trading lower after Baird downgraded the stock from Outperform to Neutral and cut its price target from $153 to $137.

In the preceding three months, 5 analysts have released ratings for Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $161.0, a high estimate of $177.00, and a low estimate of $137.00. This current average represents a 7.11% decrease from the previous average price target of $173.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1744722121_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Tenet Healthcare among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Michael Ha &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $137.00&#x7C;$153.00 &#x7C; 
&#x7C;Jason Cassorla &#x7C;Guggenheim &#x7C;Announces &#x7C;Buy &#x7C; $165.00&#x7C;- &#x7C; 
&#x7C;Craig Hettenbach &#x7C;Morgan Stanley &#x7C;Announces &#x7C;Overweight &#x7C; $165.00&#x7C;- &#x7C; 
&#x7C;Sarah James &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Overweight &#x7C; $177.00&#x7C;$177.00 &#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $161.00&#x7C;$190.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Tenet Healthcare. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Tenet Healthcare's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Tenet Healthcare's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/THC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Tenet Healthcare analyst ratings.</a>
<h2>Unveiling the Story Behind Tenet Healthcare</h2>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Tenet Healthcare's Economic Impact: An Analysis</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Negative Revenue Trend: Examining Tenet Healthcare's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -5.71% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Tenet Healthcare's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.27% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.95%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Tenet Healthcare's ROA excels beyond industry benchmarks, reaching 1.09%. This signifies efficient management of assets and strong financial health.
Debt Management: Tenet Healthcare's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 3.16.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Tenet Healthcare Stock: Analyst Perspectives (5 Ratings)

Baird analyst Michael Ha downgrades Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) from Outperform to Neutral and lowers the price target from $153 to $137.

Downgrades

Baird Downgrades Tenet Healthcare to Neutral, Lowers Price Target to $137

Guggenheim analyst Jason Cassorla initiates coverage on Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy rating and announces Price Target of $165.

Initiation

Guggenheim Initiates Coverage On Tenet Healthcare with Buy Rating, Announces Price Target of $165

Press Releases

Tenet to Report its Third Quarter 2024 Results on October 29th

Tenet to Participate in the UBS Global Healthcare Conference

Tenet Reports Strong Third Quarter 2024 Results; Raises 2024 Financial Outlook

Health Care

General

Commure to Deploy Ambient AI Platform to Tenet Physician Resources for Enhanced Clinical Workflows

Tenet to Report its Fourth Quarter 2024 Results on February 12th

Tenet Reports Strong Fourth Quarter and FY 2024 Results; Provides 2025 Financial Outlook

Comments

Tenet Healthcare

Intérêt court

Tenet Healthcare (NYSE:THC) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL